Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
about
Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research DatabaseRisk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.Medicine by media: did a critical television documentary affect the prescribing of cyproterone--estradiol (Diane-35)?Examining the use of oral contraceptives in the management of acne.Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study.Diane-35 (cyproterone acetate): safety concernsHormonal therapies in acne.Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.New developments in contraceptive drugs for use by women.Estrogens, progestogens and thrombosis.Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databasesHormones and pregnancy: thromboembolic risks for women.Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control studyMetabolic and clinical effects of progestogens.Combined hormonal contraception and venous thromboembolism.Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosisVenous thromboembolism in women.Hormonal contraception and risk of venous thromboembolism: national follow-up study.The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.Hormone therapies and venous thromboembolism: where are we now?Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.First-use risks.Venous thrombosis and oral contraceptives: current status.Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor.Thrombotic risk minimization for Diane-35 and generics.A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome.Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women.Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database
P2860
Q24530178-D9B31A21-7D83-4EC3-A4BE-9FA9DBBD2982Q24634077-4A5A054C-9D7B-4A5F-ACD2-63105718BE2EQ33879375-591C71C5-025C-480C-A0FD-8D1399BC9733Q34132570-3A80C99A-3015-4D0A-A747-309376BF2FEDQ34272111-A999CB70-7460-4EE2-BBD8-E21EA1933342Q34288033-70BFCFDF-EBB8-4379-A295-A7F0898EAC51Q34536900-F7A4A75D-01D8-41D0-884D-9951B6D03F4BQ34706886-E20B6910-3488-4B98-859A-E57F294DDC69Q34836664-79702334-A562-4083-B28C-C0708A366EC7Q34841753-DF848F12-B5CB-4A44-B5CD-E6CD2E6CFB88Q35181580-0188FC0B-D434-43FD-98ED-BB9FB64988CDQ35651010-A972DD04-35FE-4D81-8E07-85920F98B659Q35852845-93518A17-8FCA-4232-A861-78F990F29C03Q36199544-F70FA832-4255-4BF9-8196-DBE352BCE0B8Q36631196-16A6DF30-6D7C-4C7F-BFC8-3558D5CC3539Q36845040-7C3788F2-89DB-4326-BF48-6BDFAD045527Q37067199-0E38C986-D500-4F71-8847-C6D96405E157Q37238147-693563F4-A84F-4F52-BCC1-253C57818FABQ37305290-52ECEEC1-02AC-4336-BBD6-D30895B00A72Q37305295-91622A97-C3EC-4905-BEAA-3F6288963981Q37813184-BC62F9D9-6E5B-4436-8A11-3C217D3B8D0BQ37975229-6D316C0A-CE5E-41D2-954F-D918C4759CD6Q42867616-2D2A8C17-4A44-45C7-BF54-63AC5AC73F37Q43267080-3C78F0FE-685A-4BF3-9D37-129DFA3861F0Q45154446-BD9F441C-F170-4940-BA4F-8AAD9F0D4AB8Q46287303-E4273EB0-A53A-4A12-BD16-75EBC39D8832Q46859775-D3484416-671E-4849-A65E-A72F9B3CCF68Q48282941-74E3F135-FCC6-41BF-91D1-03619BECFE8DQ48517068-2677E550-DFC5-4774-952A-2B304CECE14AQ50744133-DACFDDC2-57BE-4BF1-8D37-4008D805B5ABQ51827826-CFAAE1D0-4BC3-4BC3-888B-5C4B813C6809Q57407574-ED63A2D1-2424-4C79-A5BA-B8D2B4322E01
P2860
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@en
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@nl
type
label
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@en
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@nl
prefLabel
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@en
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@nl
P1433
P1476
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
@en
P2093
C Vasilakis-Scaramozza
P304
P356
10.1016/S0140-6736(01)06522-9
P407
P50
P577
2001-10-01T00:00:00Z